Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122564 | 0.88 | TSHR (0.46) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL29870381 | 0.82 | ALOX15 (0.52) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL6542411 | 0.82 | CHEK1 (0.41) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL25335 | 0.82 | ALOX15 (0.52) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL574298 | 0.81 | ALOX5 (0.50) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL29710612 | 0.80 | CHEK1 (0.40) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL11453783 | 0.80 | ALOX15 (0.50) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL1569443 | 0.80 | CHEK1 (0.40) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL68224 | 0.79 | ALOX15 (0.54) | TSHRGFERALOX15ALDH1A1CYP1A2 | |
| SCHEMBL573894 | 0.78 | TYR (0.52) | TSHRGFERALOX15ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | claimed |
| US-12448392-B2 | Spiropiperidine derivatives | CEPHALON LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240166661-A1 | Spiropiperidine Derivatives | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-11878982-B2 | Spiropiperidine derivatives | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-20210284651-A1 | Spiropiperidine Derivatives | CEPHALON LLC | 2021-09-16 | — | — | US | disclosed |
| US-11046707-B2 | Spiropiperidine derivatives | 89BIO LTD (IL) | 2021-06-29 | — | — | US | disclosed |
| US-20200031840-A1 | SPIROPIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| EP-3554637-A1 | SPIROPIPERIDINE DERIVATIVES | 89Bio Ltd. (IL) | 2019-10-23 | — | — | EP | disclosed |
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3191454-B1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| US-5843972-A | Heterocyclic β-adrenergic agonists | PFIZER INC. (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |
| EP-0801060-A1 | Heterocyclic Beta-3 Adrenergenic Agonists | PFIZER INC. (US) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878982-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | TSHR 2369/4885GFER 728/4885ALOX15 151/4885 |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | TSHR 2624/4885GFER 673/4885ALOX15 14/4885 |
| US-20210284651-A1 | Spiropiperidine Derivatives | FASN, FADS2, SCD5 | TSHR 2369/4885GFER 728/4885ALOX15 151/4885 |
| US-20200031840-A1 | SPIROPIPERIDINE DERIVATIVES | FASN, FADS2, SCD5 | TSHR 2369/4885GFER 728/4885ALOX15 151/4885 |
| US-12448392-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | TSHR 2369/4885GFER 728/4885ALOX15 151/4885 |
| US-20240166661-A1 | Spiropiperidine Derivatives | FASN, FADS2, SCD5 | TSHR 2369/4885GFER 728/4885ALOX15 151/4885 |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | TSHR 322/4885GFER 1970/4885ALOX15 712/4885 |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | TSHR 4819/4885GFER 3980/4885ALOX15 3250/4885 |
| US-11046707-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | TSHR 2369/4885GFER 728/4885ALOX15 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.